International Psoriasis Council
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the initiation of VISIBLE. VISIBLE is a first-of-its-kind, large-scale prospective clinical
A research group led by Catherine Smith from St John’s Institute of Dermatology described humoral and cellular immunity.
In the April 2021 issue of the Lancet, four of our esteemed colleagues in the IPC published an updated and
According to a new paper published by the team behind the PsoProtect registry, psoriasis patients treated with biologics are at
In moderate to severe psoriasis, there has been a long-lasting tradition to define outcome as a relative change from baseline
Soon after COVID-19 was declared a pandemic, the question if particular patient groups – those with immune-mediated inflammatory disease (IMID)